Tilray Brands 2026 Q1 Earnings Strong Performance as Net Income Surges 104%

Tilray Brands reported a significant turnaround in its fiscal 2026 Q1 earnings, delivering a net income of $1.5 million, a 104.4% swing from a net loss a year prior. The company not only exceeded revenue expectations with a 4.7% year-over-year increase to $209.50 million but also reaffirmed its adjusted EBITDA guidance of $62–$72 million for fiscal 2026.

Revenue

Tilray Brands achieved a 4.7% year-over-year increase in total revenue, reaching $209.50 million in fiscal 2026 Q1. The beverage business contributed $55.74 million, the cannabis business generated $64.51 million, the distribution segment accounted for $74.01 million, and the wellness segment added $15.24 million to the company’s overall performance.

Earnings/Net Income

Tilray Brands delivered a remarkable turnaround in its Q1 earnings, reporting a net income of $1.51 million in fiscal 2026, a 104.4% improvement from the $-34.65 million net loss in the same period the previous year. The company also maintained a stable EPS of $0.00, marking a significant financial milestone.

Price Action

Following the earnings report, Tilray Brands' stock experienced a strong price surge. The stock rose 5.53% on the latest trading day, climbed 30.43% during the previous full trading week, and surged 84.21% month-to-date.

Post Earnings Price Action Review

Irwin Simon, CEO of Tilray Brands, emphasized the company’s strategic focus on innovation, SKU rationalization under Project 420, and operational efficiency, which contributed to $25 million in savings. He highlighted the company's leadership in the global cannabis market and expressed optimism about regulatory developments in the U.S. and Europe. The company plans to expand its market share, leverage regulatory reforms, and continue reducing debt to strengthen its balance sheet.

CEO Commentary

Irwin D. Simon, Chairman and Chief Executive Officer of Tilray Brands, stated that the company's first quarter results reflect the effectiveness of its strategic vision and disciplined execution. He emphasized Tilray's position as a leader in the cannabis, beverage, and wellness sectors, with a global platform poised to drive long-term value for shareholders. Simon expressed confidence in the company's ability to adapt and scale, leveraging innovation and strategic initiatives to capitalize on emerging opportunities.

Guidance

Tilray Brands reaffirmed its adjusted EBITDA guidance of $62–$72 million for fiscal year 2026. The company also outlined its strategic goals, including expanding its U.S. medical cannabis market share, growing its international cannabis operations, and expanding its hemp-derived Delta-9 THC beverages. Additionally, the company plans to continue reducing debt and strengthening its balance sheet while exploring acquisitions and innovation opportunities.

Additional News

Tilray Brands reported a significant improvement in its balance sheet, with cash reserves reaching $265 million and net debt reduced to $4 million. The company also achieved a 12% growth in Canadian adult-use cannabis gross revenue and a 10% increase in international cannabis revenue. Tilray Brands plans to leverage its EU GMP-certified production to expand its market presence and is focused on tripling medical cannabis distribution in Germany via CC Pharma. The company also highlighted its commitment to regulatory progress and expanding access to cannabis products globally.